Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 6127 | 2015 |
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4211 | 2018 |
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 2980 | 2019 |
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy R Cristescu, R Mogg, M Ayers, A Albright, E Murphy, J Yearley, X Sher, ... Science 362 (6411), eaar3593, 2018 | 1912 | 2018 |
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial P Sharma, M Retz, A Siefker-Radtke, A Baron, A Necchi, J Bedke, ... The lancet oncology 18 (3), 312-322, 2017 | 1770 | 2017 |
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy W Choi, S Porten, S Kim, D Willis, ER Plimack, J Hoffman-Censits, B Roth, ... Cancer cell 25 (2), 152-165, 2014 | 1700 | 2014 |
Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ... Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019 | 1287 | 2019 |
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase … AV Balar, D Castellano, PH O'Donnell, P Grivas, J Vuky, T Powles, ... The Lancet Oncology 18 (11), 1483-1492, 2017 | 1285 | 2017 |
Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial RJ Motzer, BI Rini, DF McDermott, BG Redman, TM Kuzel, MR Harrison, ... Journal of clinical oncology 33 (13), 1430-1437, 2015 | 1187 | 2015 |
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial CE Kyriakopoulos, YH Chen, MA Carducci, G Liu, DF Jarrard, NM Hahn, ... Journal of Clinical Oncology 36 (11), 1080-1087, 2018 | 1018 | 2018 |
Prostate cancer, version 1.2016 JL Mohler, AJ Armstrong, RR Bahnson, AV D'Amico, BJ Davis, ... Journal of the National Comprehensive Cancer Network 14 (1), 19-30, 2016 | 770 | 2016 |
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 739 | 2019 |
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open … T Powles, ER Plimack, D Soulières, T Waddell, V Stus, R Gafanov, ... The Lancet Oncology 21 (12), 1563-1573, 2020 | 648 | 2020 |
Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, S Bhayani, WP Bro, SS Chang, ... Journal of the National Comprehensive Cancer Network 15 (6), 804-834, 2017 | 596 | 2017 |
Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 2020 | 547 | 2020 |
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, ... ESMO open 5 (6), e001079, 2020 | 490 | 2020 |
Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer ER Plimack, RL Dunbrack, TA Brennan, MD Andrake, Y Zhou, ... European urology 68 (6), 959-967, 2015 | 471 | 2015 |
Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ... Journal of Clinical Oncology 35 (34), 3851-3858, 2017 | 463 | 2017 |
Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ... Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022 | 432 | 2022 |
Bladder cancer PE Clark, N Agarwal, MC Biagioli, MA Eisenberger, RE Greenberg, ... Journal of the National Comprehensive Cancer Network 11 (4), 446-475, 2013 | 423 | 2013 |